Innoviva - INVA Total Company Value-to-Revenue Ratio

Public company logo of Innoviva (INVA)

Innoviva, Inc. finances advanced biopharmaceutical developments, generating profit from royalties on therapeutic products. The EV/Sales history illustrates the dynamics of the business's market valuation, with the value 2186.19 indicating the valuation status relative to revenue. However, the delegation of operational management to external contractors and the complete absence of proprietary R&D releases place the company in a state of technological stagnation.

INVA: Innoviva Corp EV/Sales Multiple 11/23/2025 - 11/20/2026

INVA (Innoviva, Inc.): analytical breakdowns and indicator data

- share price and consensus valuation forecast:
Initial company analysis:inva.com, INVA
Original product of Innoviva Therapeutics

This indicator determines the market value of the business accounting for net debt relative to sales volume. By analyzing the EV/Sales ratio, an investor assesses the premium paid per unit of revenue compared to NYSE industry benchmarks. Inflated values signal a risk of correction in the event of revenue stagnation. For Innoviva, Inc. (INVA), a high valuation is justified by stable royalties from GSK drugs. Patent protection and FDA compliance ensure the sustainability of this cash generator.